Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Strangely quiet

<< Previous

Bullboard Posts

Next >>

Comment by Lee430on Oct 25, 2022 10:33am

129 Views

Post# 35046444

RE:Strangely quiet

Maybe we are on the cusp of 2 responders for a go signal with Break Through Therapy designation!

Joemare wrote: Can't put my fingers on it.
Last couple of weeks of trading, yesterday was also bizarre. Again, the conference call......

What do they have to 'hide'?
a) Good results are due any moment?
b) Deal of some sort?
c) Clinical trial delays
d) Protocol amendment to fast-track patient accrual?
e) Departure of an executive?

What is it that they can't get ahead of the game?